421 related articles for article (PubMed ID: 30043874)
1. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
5. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging biologics for ulcerative colitis.
Park SC; Jeen YT
Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
13. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Varyani F; Argyriou K; Phillips F; Tsakiridou E; Moran GW
Drug Des Devel Ther; 2019; 13():4091-4105. PubMed ID: 31819376
[TBL] [Abstract][Full Text] [Related]
14. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
16. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Danese S; D'Amico F; Bonovas S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2018 Sep; 24(10):2106-2112. PubMed ID: 29697791
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A; Castro-Poceiro J; Panés J
Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
[TBL] [Abstract][Full Text] [Related]
20. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
